RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/
RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.
“The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimistic and incredibly enthusiastic about what the future holds,” said Prof. Dr. med. Dent., Patrick Schmidlin, head of the Division of Periodontology at the University of Zurich, who serves as one of the investigators in RevBio’s pivotal clinical trial. “This breakthrough material promises to open a new chapter in dental care, redefining what is possible in regenerative dentistry.”
RevBio received regulatory and ethics committee approvals for five clinical sites consisting of one in Switzerland, two in Belgium, one in Spain, and one in the United Kingdom. Each site is expected to enroll between 12-25 patients for a total of approximately 75 patients. The investigators who are approved to enroll patients in this clinical trial are Prof. Dr. med. Dent., PhD, Patrick Schmidlin, head of the Department of Periodontology at the University of Zurich, Ana Castro, BDS MSc PhD, Clinical Head Department Periodontology at the Catholic University of Leuven, France Lambert, DDS, PhD, Professor and Head of Periodontology, Oral Surgery, and Implant Surgery at the University of Liege, Arturo Llobell, DDS, MS, a periodontist in private practice in Valencia, Spain, and Azim Malik, BDS, MFDS RCSEd, DipPCD RCSI, DClinDent, MPerio RCSEd, a periodontist and implant specialist in private practice in London, United Kingdom.
When teeth are extracted due to damage from traumatic injuries, tooth decay, or gum disease, the current standard of care consists of multiple staged surgical procedures to restore a patient’s dentition with prosthetic crowns supported by dental implants. Frequently, extraction sites are too large for dental implants to achieve primary stability through conventional mechanical engagement. Instead, patients must undergo a costly, complex, and lengthy process including a preliminary bone grafting surgery before receiving a dental implant. The use of TETRANITE to stabilize an unstable implant will allow for the immediate placement of dental implants which otherwise could not be placed until the initial bone graft has healed to form new bone. As a result, the TETRANITE® biomaterial will help reduce the duration and complexity of these dental implant procedures, lessen patient pain and recovery time, and reduce the overall cost of care thereby providing greater patient access for the treatment of tooth loss.
"The approval to conduct this pivotal clinical trial and the successful enrollment of the first 30 patients is a watershed moment for RevBio," said Alan Pollack, DDS, RevBio’s Senior Director of Dental Clinical Operations. “This clinical trial has the potential to significantly accelerate the timeframe when this promising bone adhesive technology can be used in the field of dentistry.”
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306978603/en/
Contacts
Michael Tiedemann
mtiedemann@revbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Trust in Digital Services Declines, Finds Thales18.3.2025 10:00:00 EET | Press release
Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands and services, their privacy expectations, and how brands can earn their trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318397240/en/ ©Thales This decline in trust comes as nearly one in five (19%) have been informed that their personal data has been compromised in the past year. Consequently, 82% have abandoned a brand in the past 12 months due to concerns about how their personal data was bein
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 10:00:00 EET | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments into new companies across Europe driving cutting-edge innovation in biotechnology. Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer’s disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generatio
ATLAS Welcomes Strengthened Commitment to Increased Shareholder Returns from SES Board18.3.2025 09:43:00 EET | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist listed infrastructure investor managing funds on behalf of long-term infrastructure clients. ATLAS’s actively managed accounts currently hold in aggregate a greater than 10% voting interest and 12.5% economic interest in SES S.A (“SES” or the “Company”). ATLAS supports the decision from the SES Board of Directors (“the Board”) to further strengthen Company governance through a modernisation of the Board structure and composition. Introducing further capital markets experience into a reduced Board of 9 increases alignment of stakeholder interests. ATLAS looks forward to continuing its engagement with the Board, the Nomination Committee and other Significant Stakeholders to assist with finding the best possible candidate during the upcoming selection process. Further, ATLAS welcomes the decision by the Board to endorse Shareholder Resolution 22 (“Resolution on Capital Return to Shareholders”) at the 2025 Annual General Meeting. The Board’s s
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 08:00:00 EET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 08:00:00 EET | Press release
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asgar MD, Dr Samir Kapadia MD, and Dr Nicolas van Mieghem MD. The SAB is chaired by Dr Martin Leon, Professor of Medicine at New York’s Columbia University Irving Med
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom